Research Summary
Research Summary
11/13/2026
Brian McCurdy
The randomized controlled trial found mobile PrEP and MOUD services did not improve medication use versus peer navigation alone among people who inject drugs, although mortality was lower.
11/13/2026
FDA Alert
FDA Alert
10/12/2026
Ashton L. Stahl
The FDA expands dolutegravir treatment to newborns from birth to 4 weeks who weigh at least 2 kg.
10/12/2026
FDA Approval Timeline
Notable FDA Approvals
FDA Approval Timeline
09/01/2026
August 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a...
09/01/2026
RESEARCH SUMMARY
RESEARCH SUMMARY
07/31/2026
Anthony Calabro, MA
In a multicenter dose de-escalation and expansion study of adults with HIV-related DLBCL, ibrutinib plus R-da-EPOCH showed manageable toxicity and clinical activity, with 3-year event-free and overall...
07/31/2026
Research Summary
Research Summary
06/09/2026
Ashton L. Stahl
A phase 3 trial found that switching from bictegravir–emtricitabine–tenofovir alafenamide to once-daily bictegravir–lenacapavir maintained viral suppression in adults with HIV-1.
06/09/2026
FDA Approval
FDA Approval
05/13/2026
Anthony Calabro, MA
The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.
05/13/2026
Timeline Snapshot
physicians discussing cases
Timeline Snapshot
05/07/2026
April 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
05/07/2026
Conference Coverage
Conference Coverage
04/08/2026
Ashton L. Stahl
A large national database study presented at CROI 2026 in Denver, CO, reports that 5-year survival remains lower for people with HIV compared with people without HIV across most treatment modalities for...
04/08/2026
Research Summary
Research Summary
03/12/2026
Kate Young
A large US cohort study examined hepatitis B virus (HBV) monitoring practices and the risk of HBV reactivation and hepatitis flares during interruptions of tenofovir-containing antiretroviral therapy among...
03/12/2026
Research Summary
Research Summary
03/10/2026
Anthony Calabro, MA
In the phase 3 ACTG A5359 LATITUDE trial, investigators evaluated whether monthly, long-acting injectable cabotegravir plus rilpivirine could reduce regimen failure compared with standard oral...
03/10/2026